ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Primary Endpoint Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study: Nanvuranlat, LAT1 Inhibitor for Patients With Pretreated Advanced Refractory BTC

56 views
February 23, 2023
Comments 0
Login to view comments. Click here to Login